Cargando…

Biomarker screening in fetal growth restriction based on multiple RNA-seq studies

OBJECTIVE: Fetal growth restriction (FGR) is a severe pathological complication associated with compromised fetal development. The early diagnosis and prediction for FGR are still unclear. Sequencing technologies present a huge opportunity to identify novel biomarkers. However, limitation of individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaohui, He, Xin, Li, Zhengpeng, Chen, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637895/
https://www.ncbi.nlm.nih.gov/pubmed/37954535
http://dx.doi.org/10.1016/j.eurox.2023.100259
_version_ 1785133496220516352
author Li, Xiaohui
He, Xin
Li, Zhengpeng
Chen, Yi
author_facet Li, Xiaohui
He, Xin
Li, Zhengpeng
Chen, Yi
author_sort Li, Xiaohui
collection PubMed
description OBJECTIVE: Fetal growth restriction (FGR) is a severe pathological complication associated with compromised fetal development. The early diagnosis and prediction for FGR are still unclear. Sequencing technologies present a huge opportunity to identify novel biomarkers. However, limitation of individual studies (e.g., long lists of dysregulated genes, small sample size and conflicting results) hinders the selection of the best-matched ones. STUDY DESIGN: A multi-step bioinformatics analysis was performed. We separately reanalyzed data from four public RNA-seq studies, followed by a combined analysis of individual results. The differentially expressed genes (DEGs) were identified based on DESeq2. Then, function enrichment analyses and protein-protein interaction network (PPI) were conducted to screen for hub genes. The results were further verified by using external microarray data. RESULTS: A total of 65 dysregulated genes (50 down and 15 upregulated) were identified in FGR compared to controls. Function enrichment and PPI analysis revealed ten hub genes closely related to FGR. Validation analysis found four downregulated candidate biomarkers (CEACAM6, SCUBE2, DEFA4, and MPO) for FGR. CONCLUSIONS: The use of omics tools to explore mechanism of pregnancies disorders contributes to improvements in obstetric clinical practice.
format Online
Article
Text
id pubmed-10637895
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-106378952023-11-11 Biomarker screening in fetal growth restriction based on multiple RNA-seq studies Li, Xiaohui He, Xin Li, Zhengpeng Chen, Yi Eur J Obstet Gynecol Reprod Biol X Obstetrics and Maternal Fetal Medicine OBJECTIVE: Fetal growth restriction (FGR) is a severe pathological complication associated with compromised fetal development. The early diagnosis and prediction for FGR are still unclear. Sequencing technologies present a huge opportunity to identify novel biomarkers. However, limitation of individual studies (e.g., long lists of dysregulated genes, small sample size and conflicting results) hinders the selection of the best-matched ones. STUDY DESIGN: A multi-step bioinformatics analysis was performed. We separately reanalyzed data from four public RNA-seq studies, followed by a combined analysis of individual results. The differentially expressed genes (DEGs) were identified based on DESeq2. Then, function enrichment analyses and protein-protein interaction network (PPI) were conducted to screen for hub genes. The results were further verified by using external microarray data. RESULTS: A total of 65 dysregulated genes (50 down and 15 upregulated) were identified in FGR compared to controls. Function enrichment and PPI analysis revealed ten hub genes closely related to FGR. Validation analysis found four downregulated candidate biomarkers (CEACAM6, SCUBE2, DEFA4, and MPO) for FGR. CONCLUSIONS: The use of omics tools to explore mechanism of pregnancies disorders contributes to improvements in obstetric clinical practice. Elsevier 2023-10-31 /pmc/articles/PMC10637895/ /pubmed/37954535 http://dx.doi.org/10.1016/j.eurox.2023.100259 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Obstetrics and Maternal Fetal Medicine
Li, Xiaohui
He, Xin
Li, Zhengpeng
Chen, Yi
Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
title Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
title_full Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
title_fullStr Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
title_full_unstemmed Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
title_short Biomarker screening in fetal growth restriction based on multiple RNA-seq studies
title_sort biomarker screening in fetal growth restriction based on multiple rna-seq studies
topic Obstetrics and Maternal Fetal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637895/
https://www.ncbi.nlm.nih.gov/pubmed/37954535
http://dx.doi.org/10.1016/j.eurox.2023.100259
work_keys_str_mv AT lixiaohui biomarkerscreeninginfetalgrowthrestrictionbasedonmultiplernaseqstudies
AT hexin biomarkerscreeninginfetalgrowthrestrictionbasedonmultiplernaseqstudies
AT lizhengpeng biomarkerscreeninginfetalgrowthrestrictionbasedonmultiplernaseqstudies
AT chenyi biomarkerscreeninginfetalgrowthrestrictionbasedonmultiplernaseqstudies